Search News Archives
Special Offers and Promotions
IT Solutions and Laboratory Automation
Conferences | Events
CRISPR-Cas9 Knock-In Efficiency Enhanced Using Small-Molecule Inhibitor Pair, Study Shows
Promega scientists contribute to new research to improve precision and efficiency of groundbreaking gene editing technique
A new study published in Nature Communications demonstrates how small molecule inhibitors can be used to improve the precision and efficiency of CRISPR-Cas9 gene editing. The results demonstrate how this groundbreaking technique can be enhanced by using two inhibitors to boost insertion rates and reduce off-target effects. Their findings are key to advancing the use of CRISPR techniques in research and clinical applications using a wide range of cell lines.
Improved Genome Editing with CRISPR-Cas9
CRISPR-Cas9 is a genome editing technique that has become an indispensable tool in biomedical research since it was first unveiled in 2012. Researchers can use the technique to cut DNA at specific sites and insert or remove genetic material, enabling a level of genetic manipulation that was previously impossible.
In the Nature Communications paper, the authors analysed a library of 20,548 small molecules to develop strategies for improving this gene editing technique. They identified two inhibitors targeting the proteins DNA-dependent Protein Kinase (DNA-PK) and DNA Polymerase Theta (PolΘ) and demonstrated that the combination of these two molecules dramatically increased the performance of “knock-in” gene editing. This strategy, dubbed 2iHDR, outperformed previously described strategies that aimed to increase knock-in efficiency with small molecule inhibitors.
This paper also documents a new system based on next-generation sequencing (NGS) that can be used to characterise the effects of inhibitors on CRISPR-Cas9. This open-access tool, which the authors named KI-Seq, enables researchers to analyse the contributions of different DNA repair pathways following CRISPR-Cas9 treatment. Unlike comparable tools, KI-Seq can be used with any cell type, including non-dividing primary cells.
Promega research scientists Marie Schwinn and Michael Slater contributed to this research led by scientists from AstraZeneca.
Read the paper, “Simultaneous inhibition of DNA-PK and PolΘ improves integration efficiency and precision of genome editing”.
Learn about Promega technologies that can be used with CRISPR-Cas9 at www.promega.com/CRISPR
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products support a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For over 40 years these tools and technologies have grown in their application and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors.